Heart Congress | Cardiology Conferences | Heart Conferences | World Cardio Agenda

Renowned Speakers

Riccardo Cappato

IRCCS Humanitas Research Hospital Italy

Sophia Chew

General Hospital Singapore

Nour Eddin Haj Mohamad

Allm INC UAE

Jean-Pierre Usdin

American Hospital of Paris France

M. Eileen Walsh

University of Toledo USA

Kevin A. Courville

Prevail Heart Clinics USA

Nattapong Thaiyanurak

Siriraj Hospital-Mahidol University Thailand

Wajih Maazouzi

University Medical Center of Rabat Morocco

Recommended Global Cardiology Webinars & Conferences

Europe & UK

Asia Pacific & Middle East

Canada

World Heart Congress 2025

About Conference

On behalf of the organizing committee of the 14^th World Heart Congress, to be held in Dubai, UAE during September 22-23, 2025, we are delighted to invite you to speak at this prestigious event. The 14^th World Heart Congress is expected to attract a global audience of leading cardiologists, researchers, healthcare professionals, and policymakers dedicated to advancing cardiovascular health. The theme for this year's congress is "Innovations in Cardiovascular Medicine: Bridging Science and Practice". We are open to various presentation formats, including keynote addresses, plenary sessions, symposia, or workshops. We would be happy to discuss your specific interests and tailor a session to best suit your expertise.

World Heart Congress 2025 will be an investigation of new research Innovation in the field of Cardiology and spread the most recent advancements in heart disease prevention and rehabilitation. Argument on new technology enhancement in the field of Cardiovascular Disease and current practices in cardiovascular therapy, Cardiac progenitor cells, Hypertension for the primary care clinician, Stent procedure, Balloon Valvuloplasty, Coronary thrombectomy, Noninvasive cardiac imaging, Heart failure, Congestive heart failure, Sports Cardiology and more. Differentiating heart disease and other cardiac conditions constitute a team of healthcare professionals, of which the Cardiology technologist is a key player.

Sessions & Tracks

Track 1: Cardiology

Cardiology research is a rapidly evolving field focused on understanding, diagnosing, and treating heart-related diseases. With cardiovascular diseases being a leading cause of death worldwide, researchers continuously seek innovative ways to improve prevention, diagnosis, and treatment. Recent advancements in cardiology research include the development of artificial intelligence (AI) for early detection of heart disease, personalized medicine approaches using genetic profiling, and breakthroughs in minimally invasive procedures such as transcatheter aortic valve replacement (TAVR). Stem cell therapy and regenerative medicine are also being explored to repair damaged heart tissue. Additionally, research on novel medications, such as SGLT2 inhibitors and PCSK9 inhibitors, has significantly improved outcomes for patients with heart failure and high cholesterol. Studies on lifestyle interventions, including diet, exercise, and stress management, continue to highlight their importance in cardiovascular health. Clinical trials play a crucial role in testing new treatments and therapies, ensuring they are safe and effective before widespread use. Advances in imaging technologies, such as cardiac MRI and 3D echocardiography, allow for more accurate diagnoses and monitoring. Overall, cardiology research is essential in reducing heart disease-related mortality and improving patients' quality of life through innovative treatments and preventive strategies.

Track 2: Heart Diseases

Heart diseases encompass a wide range of conditions affecting the heart and blood vessels, leading to serious health complications and increased mortality worldwide. The most common type is coronary artery disease (CAD), which occurs when the arteries supplying blood to the heart become narrowed or blocked due to plaque buildup, increasing the risk of heart attacks. Other heart diseases include heart failure, where the heart cannot pump blood efficiently, arrhythmias, which involve irregular heart rhythms, and valvular heart diseases, affecting the function of heart valves. Congenital heart defects, present at birth, can also impact heart function and require medical intervention. Risk factors for heart disease include high blood pressure, high cholesterol, smoking, diabetes, obesity, and a sedentary lifestyle. Stress and excessive alcohol consumption can also contribute to heart problems. Prevention strategies include a healthy diet, regular exercise, managing stress, and avoiding smoking and excessive alcohol. Advancements in medical research have led to improved diagnostic tools, medications, and surgical interventions such as angioplasty, bypass surgery, and heart transplants. Early detection and proper management are crucial for improving patient outcomes. As heart diseases remain a leading cause of death globally, continued research and awareness are essential for reducing their impact.

Track 3: Heart Failure Treatment

Heart failure treatment aims to improve symptoms, enhance quality of life, and reduce hospitalizations. It typically involves a combination of lifestyle modifications, medications, and advanced medical procedures, depending on the severity of the condition. Medications play a crucial role in managing heart failure. Common drugs include ACE inhibitors and ARBs, which help relax blood vessels, beta-blockers, which reduce heart strain, and diuretics, which help remove excess fluid. Recently, SGLT2 inhibitors have shown promise in improving outcomes for heart failure patients, even those without diabetes. Lifestyle changes are essential in managing heart failure. Patients are encouraged to follow a low-sodium diet, engage in regular exercise, monitor fluid intake, and avoid smoking and excessive alcohol consumption. For more severe cases, medical devices and surgical interventions may be necessary. Implantable cardioverter defibrillators (ICDs) help prevent sudden cardiac death, while cardiac resynchronization therapy (CRT) improves heart function. In end-stage heart failure, ventricular assist devices (VADs) or a heart transplant may be required. Advancements in regenerative medicine, stem cell therapy, and precision medicine are shaping the future of heart failure treatment, offering hope for better long-term outcomes and improved patient survival. Early diagnosis and continuous medical management remain key to effective treatment.

Track 4: Cardiovascular Medicine

Cardiovascular medicine is a specialized branch of medicine focused on diagnosing, treating, and preventing diseases related to the heart and blood vessels. It encompasses a wide range of conditions, including coronary artery disease (CAD), heart failure, arrhythmias, hypertension, and congenital heart defects. As cardiovascular diseases remain the leading cause of death worldwide, advancements in this field are crucial for improving patient outcomes. Modern cardiovascular medicine integrates innovative technologies and treatments. Advanced imaging techniques such as cardiac MRI, CT angiography, and echocardiography allow for accurate diagnosis and monitoring of heart diseases. Pharmacological advancements, including statins, anticoagulants, SGLT2 inhibitors, and PCSK9 inhibitors, have significantly improved treatment outcomes. Minimally invasive procedures, such as transcatheter aortic valve replacement (TAVR) and percutaneous coronary intervention (PCI), have revolutionized cardiac care, reducing recovery times and complications. Additionally, implantable devices like pacemakers, defibrillators, and ventricular assist devices (VADs) help manage heart rhythm disorders and advanced heart failure. Preventive cardiology emphasizes lifestyle modifications, including a heart-healthy diet, regular exercise, and smoking cessation, to reduce cardiovascular risk factors. Research in gene therapy, regenerative medicine, and artificial intelligence continues to push the boundaries of cardiovascular medicine, offering new hope for patients and enhancing long-term heart health.

Track 5: Cardiac Surgery

Cardiac surgery is a specialized field of medicine focused on the surgical treatment of heart diseases and conditions affecting the cardiovascular system. It includes procedures to treat coronary artery disease, heart valve disorders, congenital heart defects, and heart failure. With advancements in technology and surgical techniques, cardiac surgery has evolved to improve patient outcomes and recovery times. One of the most common procedures is coronary artery bypass grafting (CABG), which restores blood flow to the heart by bypassing blocked arteries. Valve repair and replacement surgeries, including aortic and mitral valve procedures, are performed to address valve dysfunctions. Congenital heart defect repairs help correct structural abnormalities present from birth. Minimally invasive and robotic-assisted cardiac surgeries are becoming more prevalent, reducing surgical trauma and hospital stays. Transcatheter procedures, such as transcatheter aortic valve replacement (TAVR) and mitral valve repair, allow for valve interventions without open-heart surgery. For advanced heart failure, ventricular assist devices (VADs) and heart transplants are life-saving options. Ongoing research in stem cell therapy and artificial heart technology is shaping the future of cardiac surgery. As techniques and technology advance, cardiac surgery continues to improve survival rates, enhance recovery, and provide better quality of life for patients.

Track 6: Hypertension

Hypertension, or high blood pressure, is a chronic condition in which the force of blood against the artery walls remains consistently too high. It is a major risk factor for heart disease, stroke, kidney failure, and other serious health issues. Blood pressure is measured in millimeters of mercury (mmHg) and is expressed as two numbers: systolic pressure (the force when the heart beats) over diastolic pressure (the force when the heart rests between beats). A normal reading is typically around 120/80 mmHg, while hypertension is diagnosed when readings consistently exceed 130/80 mmHg. There are two main types of hypertension: primary (essential) hypertension, which develops gradually over time without a specific cause, and secondary hypertension, which results from underlying conditions such as kidney disease, hormonal disorders, or certain medications. Risk factors include genetics, obesity, high salt intake, stress, smoking, excessive alcohol consumption, and a sedentary lifestyle. Hypertension is often called a “silent killer” because it may not cause noticeable symptoms until it leads to complications. Management includes lifestyle changes such as a healthy diet, regular exercise, stress reduction, and medication when necessary. Regular blood pressure monitoring is crucial for early detection and effective control.

Track 7: Heart Arrhythmia

Heart arrhythmia refers to an irregular heartbeat, occurring when the electrical impulses that control heartbeats function improperly. This can cause the heart to beat too fast (tachycardia), too slow (bradycardia), or irregularly. While some arrhythmias are harmless, others can lead to serious complications such as stroke, heart failure, or sudden cardiac arrest. There are various types of arrhythmias, including atrial fibrillation (AFib), which causes rapid and uncoordinated heartbeats in the atria, and ventricular tachycardia, which can be life-threatening if not treated promptly. Causes of arrhythmias include heart disease, high blood pressure, electrolyte imbalances, excessive caffeine or alcohol intake, stress, smoking, and certain medications. Some people may have a genetic predisposition to arrhythmias. Symptoms vary depending on the type and severity of the arrhythmia. Common signs include palpitations, dizziness, shortness of breath, chest pain, fainting, and fatigue. Diagnosis involves tests such as electrocardiograms (ECG), Holter monitoring, and echocardiograms. Treatment options depend on the cause and severity and may include lifestyle modifications, medications, pacemakers, catheter ablation, or implantable cardioverter-defibrillators (ICDs). Regular heart check-ups and managing risk factors can help prevent and control arrhythmias, ensuring better heart health.

Track 8: Personalized Medicine in Cardiovascular Treatment

Personalized medicine in cardiovascular treatment tailors medical care to an individual’s genetic profile, lifestyle, and specific health conditions. Unlike the traditional "one-size-fits-all" approach, personalized medicine considers genetic variations, biomarkers, and environmental factors to optimize prevention, diagnosis, and treatment strategies for heart diseases. Advancements in genetics and molecular biology have led to targeted therapies for conditions like hypertension, heart failure, and arrhythmias. For example, genetic testing can identify patients who may respond better to certain blood pressure medications or anticoagulants, such as warfarin, minimizing adverse effects. Additionally, biomarkers help detect cardiovascular diseases early, allowing for proactive interventions. Pharmacogenomics, a key aspect of personalized medicine, analyzes how an individual’s genes affect their response to medications. This enables doctors to prescribe the most effective drugs with the right dosage, reducing the risk of complications. For patients with high cholesterol, PCSK9 inhibitors offer a tailored alternative to statins for those who don’t respond well to traditional treatments. Advances in artificial intelligence and wearable technology also contribute to personalized cardiovascular care by providing real-time monitoring and predictive analytics. As research continues, personalized medicine promises more precise, efficient, and effective treatments, ultimately improving patient outcomes and reducing cardiovascular disease burdens.

Track 9: Pediatric Cardiology

Pediatric cardiology is a specialized branch of medicine focused on diagnosing and treating heart conditions in infants, children, and adolescents. It covers a wide range of congenital (present at birth) and acquired heart diseases, including congenital heart defects, arrhythmias, cardiomyopathies, and rheumatic heart disease. Early detection and intervention are crucial to improving outcomes and ensuring normal growth and development. Congenital heart defects (CHDs) are among the most common birth defects, affecting nearly 1% of newborns. Conditions like atrial septal defects, ventricular septal defects, and tetralogy of Fallot require careful monitoring and, in some cases, surgical intervention. Advances in fetal echocardiography allow for early diagnosis, sometimes even before birth, enabling prompt treatment after delivery. Pediatric cardiologists use various diagnostic tools, including echocardiograms, electrocardiograms (ECGs), and cardiac MRIs, to assess heart function. Treatment options range from medications and catheter-based interventions to open-heart surgery. For severe cases, heart transplantation may be necessary. Recent innovations, such as minimally invasive procedures and 3D-printed heart models for surgical planning, have improved survival rates and quality of life for children with heart conditions. With continuous advancements, pediatric cardiology plays a vital role in ensuring a healthier future for children with heart disease.

Track 10: Cardiac Pharmacology and Therapeutics

Cardiac pharmacology and therapeutics focus on the study and application of medications used to treat cardiovascular diseases, including hypertension, heart failure, arrhythmias, and coronary artery disease. These medications help regulate heart function, improve circulation, and reduce the risk of complications such as heart attacks and strokes. There are several major classes of cardiovascular drugs. Antihypertensives, such as beta-blockers, ACE inhibitors, and calcium channel blockers, help control blood pressure. Antiarrhythmic drugs, including amiodarone and lidocaine, manage irregular heart rhythms. Anticoagulants and antiplatelet agents, like warfarin and aspirin, prevent blood clots and reduce the risk of stroke and heart attacks. Statins lower cholesterol levels to prevent atherosclerosis, while diuretics help reduce fluid retention in heart failure patients. Pharmacogenomics plays an increasing role in cardiac therapeutics by tailoring drug selection and dosage based on an individual’s genetic makeup. This approach minimizes adverse effects and enhances treatment efficacy. Additionally, emerging biologics and targeted therapies, such as PCSK9 inhibitors for cholesterol management, provide new options for patients who do not respond to traditional medications. As cardiovascular diseases remain a leading cause of mortality, advancements in cardiac pharmacology continue to improve patient outcomes through safer, more effective, and personalized treatments.

Track 11: Minimally Invasive Cardiac Procedures

Minimally invasive cardiac procedures have revolutionized heart disease treatment by offering safer alternatives to traditional open-heart surgery. These techniques use small incisions, catheters, and advanced imaging to diagnose and treat cardiovascular conditions with reduced recovery time, lower risks, and minimal scarring. One of the most common procedures is percutaneous coronary intervention (PCI), also known as angioplasty, where a catheter is inserted into a blocked artery to restore blood flow, often with the placement of a stent. Transcatheter aortic valve replacement (TAVR) is another groundbreaking procedure used to treat aortic stenosis, allowing valve replacement without open surgery. MitraClip is a minimally invasive solution for mitral valve regurgitation, improving heart function without major surgery. Electrophysiology procedures, such as catheter ablation, treat arrhythmias by targeting and eliminating abnormal electrical pathways in the heart. Implantable devices like pacemakers and defibrillators can also be placed using minimally invasive techniques. These advancements have significantly improved patient outcomes, reducing hospital stays and recovery periods. As technology advances, robotic-assisted surgeries and new catheter-based interventions continue to refine minimally invasive cardiac care, making it an increasingly preferred option for patients with heart disease.

Track 12: Regenerative Medicine and Stem Cell Therapy for Heart Disease

Regenerative medicine and stem cell therapy offer promising solutions for treating heart disease by repairing damaged heart tissue and restoring function. Unlike traditional treatments that manage symptoms, these approaches aim to regenerate heart muscle and improve overall cardiac health. Stem cell therapy involves using stem cells—typically derived from bone marrow, umbilical cord blood, or induced pluripotent stem cells (iPSCs)—to repair injured heart tissue. When introduced into the heart, these cells can stimulate tissue regeneration, reduce inflammation, and promote new blood vessel growth (angiogenesis). Research has shown potential benefits for conditions such as heart failure, myocardial infarction (heart attack), and cardiomyopathies. Another innovative approach in regenerative medicine is tissue engineering, where bioengineered cardiac patches and 3D-printed heart tissues help replace damaged areas. Gene therapy is also being explored to enhance the heart’s ability to repair itself by activating specific regenerative pathways. While clinical trials have demonstrated promising results, challenges such as cell survival, immune response, and integration into heart tissue remain. However, with ongoing research and technological advancements, regenerative medicine and stem cell therapy have the potential to transform cardiovascular treatment, offering hope for patients with severe or irreversible heart disease.

Track 13: Wearable Technology and Remote Monitoring

Wearable technology and remote monitoring have transformed cardiovascular healthcare by enabling continuous heart monitoring, early disease detection, and personalized treatment adjustments. These devices help patients and doctors track heart health in real time, improving outcomes and reducing hospital visits. Popular wearable devices include smartwatches with ECG (electrocardiogram) capabilities, such as the Apple Watch and Fitbit, which detect irregular heart rhythms like atrial fibrillation (AFib). Chest patches and wearable ECG monitors provide more detailed heart activity tracking, while smart rings and blood pressure monitors measure vital signs like heart rate variability and oxygen levels. Remote monitoring devices, such as implantable loop recorders and wireless pacemakers, allow cardiologists to continuously track heart function without requiring frequent clinic visits. For heart failure patients, remote pulmonary artery pressure monitors help detect fluid buildup, preventing hospitalizations. Artificial intelligence (AI) enhances wearable technology by analyzing large amounts of heart data, predicting risks, and offering personalized health insights. These innovations empower patients to take control of their heart health while providing doctors with real-time data for better decision-making. As wearable and remote monitoring technologies advance, they will continue to play a crucial role in preventing and managing cardiovascular diseases efficiently.

Track 14: Obesity and Cardiovascular Risk

Obesity is a major risk factor for cardiovascular disease (CVD), significantly increasing the likelihood of conditions such as hypertension, heart disease, stroke, and heart failure. Excess body fat, particularly visceral fat around the abdomen, contributes to metabolic and inflammatory changes that negatively affect heart health. Obesity is closely linked to hypertension due to increased blood volume and resistance in the arteries. It also raises cholesterol levels, leading to atherosclerosis (narrowing of the arteries) and increasing the risk of heart attacks and strokes. Additionally, obesity is a primary driver of type 2 diabetes, which further elevates cardiovascular risk by damaging blood vessels and impairing circulation. Other obesity-related heart risks include sleep apnea, which can cause irregular heart rhythms (arrhythmias) and high blood pressure, and chronic inflammation, which weakens blood vessels over time. Lifestyle modifications, such as adopting a healthy diet, engaging in regular physical activity, and maintaining a healthy weight, are crucial for reducing cardiovascular risk. In some cases, medical treatments like weight-loss medications or bariatric surgery may be necessary. Managing obesity effectively can significantly lower the risk of heart disease and improve overall cardiovascular health, leading to a longer and healthier life.

Track 15: The Gut-Heart Connection

The gut-heart connection highlights the crucial role of gut health in cardiovascular disease (CVD) risk. Emerging research suggests that the gut microbiome—trillions of bacteria and other microorganisms in the digestive tract—affects heart health through metabolism, inflammation, and immune function. One key factor in this connection is gut-derived metabolites. For example, certain gut bacteria break down dietary nutrients like choline and carnitine (found in red meat and eggs) into trimethylamine N-oxide (TMAO), a compound linked to increased arterial plaque formation and a higher risk of heart disease. Conversely, beneficial gut bacteria help produce short-chain fatty acids (SCFAs) from fiber, which reduce inflammation, improve blood vessel function, and lower blood pressure. Dysbiosis, an imbalance in the gut microbiome, has been associated with obesity, diabetes, and hypertension, all of which contribute to CVD. Factors such as poor diet, antibiotic overuse, and chronic stress can disrupt gut health, leading to systemic inflammation that damages the heart and blood vessels. Maintaining a healthy gut through a fiber-rich diet, probiotics, and fermented foods may support heart health. As research continues, targeting the gut microbiome could become a novel approach for preventing and managing cardiovascular diseases.

Track 16: Preventative Cardiology and Lifestyle Medicine

Preventative cardiology and lifestyle medicine focus on reducing the risk of cardiovascular disease (CVD) through proactive measures, emphasizing lifestyle changes and early interventions. Given that heart disease remains a leading cause of death globally, prevention is crucial for improving long-term health outcomes. Key components of preventative cardiology include healthy nutrition, regular physical activity, stress management, and routine screenings. A heart-healthy diet, such as the Mediterranean or DASH diet, emphasizes whole foods, fruits, vegetables, lean proteins, and healthy fats while reducing processed foods, excess sugar, and saturated fats. Regular exercise, including aerobic activities and strength training, improves cardiovascular fitness, lowers blood pressure, and helps manage weight. Lifestyle medicine also addresses other major risk factors like smoking cessation, adequate sleep, and mental well-being. Chronic stress and poor sleep can contribute to high blood pressure, inflammation, and heart disease, making stress reduction techniques like meditation, yoga, and deep breathing beneficial for heart health. Preventative cardiology also includes regular screenings for blood pressure, cholesterol, and glucose levels to identify risks early. By adopting a proactive approach, individuals can significantly lower their chances of developing heart disease, improving both quality and longevity of life.

Track 17: Heart Transplant Complications

A heart transplant is a life-saving procedure for patients with end-stage heart failure, but it comes with potential complications that require careful management. These complications can be immediate, short-term, or long-term and may impact the success of the transplant. One of the most serious risks is organ rejection, where the immune system attacks the new heart. To prevent this, patients take lifelong immunosuppressive medications, but these drugs increase susceptibility to infections by weakening the immune response. Graft failure, where the transplanted heart does not function properly, can occur early (primary graft dysfunction) or later due to chronic rejection. Other complications include coronary allograft vasculopathy (CAV), a condition where the coronary arteries narrow over time, leading to heart failure or sudden cardiac arrest. Kidney damage is another concern, as immunosuppressants can harm kidney function. Patients may also experience high blood pressure, diabetes, and weight gain due to medication side effects. Psychological challenges, such as anxiety and depression, can affect transplant recipients as they adjust to lifelong medical care. Regular monitoring, adherence to medications, and a healthy lifestyle are essential to minimizing complications and ensuring the long-term success of a heart transplant.

Track 18: Heart Disease in Women

Heart disease in women is a leading cause of death, yet it remains underdiagnosed and often presents with different symptoms than in men. While chest pain is a common warning sign for both sexes, women may also experience atypical symptoms such as shortness of breath, nausea, fatigue, dizziness, and back or jaw pain, which can lead to delayed diagnosis and treatment. Several unique risk factors increase heart disease risk in women. Hormonal changes, particularly after menopause, reduce protective estrogen levels, leading to higher blood pressure, cholesterol, and arterial plaque buildup. Pregnancy-related conditions, such as gestational diabetes and preeclampsia, also raise the long-term risk of cardiovascular disease. Autoimmune disorders, which are more common in women, have been linked to heart complications as well. Women often develop microvascular disease, affecting small arteries rather than major coronary arteries, making detection more challenging. Psychosocial factors, such as high stress, anxiety, and depression, also contribute to cardiovascular risk. Prevention includes adopting a heart-healthy lifestyle, managing blood pressure and cholesterol, and undergoing regular screenings. Increased awareness, research, and gender-specific approaches to diagnosis and treatment are essential for improving heart health outcomes in women.

Track 19: AI and Machine Learning in Cardiology

Artificial intelligence (AI) and machine learning (ML) in cardiology are transforming heart disease diagnosis, treatment, and prevention by enhancing data analysis, improving accuracy, and personalizing patient care. These technologies analyze vast amounts of medical data, including electrocardiograms (ECGs), imaging scans, and electronic health records, to detect patterns that may be overlooked by human clinicians. AI-powered algorithms have significantly improved early diagnosis of heart conditions. For example, AI can analyze ECGs to detect arrhythmias like atrial fibrillation or predict the risk of sudden cardiac arrest. In cardiac imaging, ML enhances echocardiograms, CT scans, and MRIs, allowing for more precise identification of structural abnormalities and coronary artery disease. AI also plays a role in predictive analytics, helping to assess a patient’s likelihood of developing heart disease based on genetic, lifestyle, and clinical data. Additionally, robot-assisted surgeries use AI to enhance precision in minimally invasive heart procedures. Wearable technology integrated with AI enables real-time heart monitoring, providing early warnings for conditions like high blood pressure and heart failure. As AI continues to evolve, it holds great potential for improving patient outcomes, reducing healthcare costs, and personalizing treatments, making cardiology more efficient and proactive.

Track 20: The Role of Artificial Hearts and Mechanical Circulatory Support

Artificial hearts and mechanical circulatory support (MCS) devices play a crucial role in treating patients with end-stage heart failure who are awaiting a heart transplant or are ineligible for one. These advanced technologies help maintain blood circulation and improve survival rates in critically ill patients. A total artificial heart (TAH) is a device that completely replaces the heart, taking over both pumping functions of the ventricles. It is used for patients with severe biventricular failure who cannot survive with traditional therapies. Modern TAHs, such as the SynCardia Total Artificial Heart, provide a temporary or long-term solution for patients waiting for a transplant. More commonly, ventricular assist devices (VADs) support the failing heart by assisting either the left ventricle (LVAD), right ventricle (RVAD), or both (BiVAD). LVADs, such as the HeartMate 3, help pump blood from the left ventricle to the aorta, relieving strain on the heart. These devices can be a bridge to transplant (BTT) or a destination therapy (DT) for patients who are not eligible for transplantation. Although artificial hearts and VADs improve survival and quality of life, complications like blood clots, infections, and device malfunctions require careful monitoring. Advances in technology continue to enhance their safety and effectiveness, offering new hope for heart failure patients.

Track 21: Cardiac Rehabilitation and Patient Care Innovations

Cardiac rehabilitation (CR) is a medically supervised program designed to improve heart health and recovery after heart attacks, heart surgery, or heart failure. It combines exercise training, education, and lifestyle counseling to help patients regain strength, reduce cardiovascular risk, and improve overall well-being. Traditional CR programs focus on structured exercise, dietary guidance, smoking cessation, stress management, and medication adherence. Patients work with cardiologists, physiotherapists, dietitians, and mental health professionals to create personalized recovery plans. Studies show that CR significantly lowers the risk of future heart events and hospitalizations. Recent patient care innovations have expanded access and effectiveness. Telehealth and virtual cardiac rehab programs allow patients to participate from home, using wearable devices to monitor heart rate, blood pressure, and physical activity remotely. AI-driven coaching platforms provide real-time feedback and motivation. Other innovations include personalized rehabilitation plans based on genetic and biomarker analysis, helping tailor treatments for better results. Additionally, community-based and mobile CR units improve access for underserved populations. By integrating technology, behavioral science, and personalized medicine, modern cardiac rehabilitation enhances patient engagement and long-term adherence, leading to better recovery, reduced readmissions, and improved quality of life for heart patients.

Track 22: Cardiac Imaging Advances

Advances in cardiac imaging have significantly improved the diagnosis, treatment, and monitoring of heart disease, enabling earlier detection and more precise management of cardiovascular conditions. Modern imaging technologies provide high-resolution, real-time visualization of the heart’s structure and function, reducing the need for invasive procedures. Echocardiography, particularly 3D and contrast-enhanced echocardiography, offers detailed heart imaging, helping diagnose valve diseases, cardiomyopathies, and heart failure. Speckle-tracking echocardiography (STE) allows for early detection of subtle heart muscle dysfunction before symptoms appear. Cardiac magnetic resonance imaging (CMR) provides high-detail images of heart tissues, making it essential for assessing cardiomyopathies, congenital heart disease, and inflammation-related conditions like myocarditis. CT coronary angiography (CCTA) is a noninvasive method for detecting coronary artery disease with exceptional accuracy, reducing the need for traditional catheterization. Nuclear imaging techniques, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), assess blood flow and detect ischemia or scarred heart tissue, aiding in risk assessment and treatment planning. Artificial intelligence (AI) is revolutionizing cardiac imaging by enhancing image interpretation, automating analysis, and predicting disease progression. These innovations improve diagnostic accuracy, patient safety, and treatment outcomes, shaping the future of cardiovascular care.

Track 23: Cases reports in Cardiology

Cardiology case reports give an appropriate assemblage for all cardiologists by rendering their important clinical cases of late occurrence. Studying from medical cases provides valuable experience for clinicians, students and paramedical staff -members. Rare medical reports and conditions discovered through the latest methods of examination are reinforced. Furthermore, studying diagnostic methods from medical cases and interpretation of symptoms is significant to train and increase the processes which are being used in the clinical field.

Market Analysis

The global market for cardiovascular drugs, which includes medications for various heart diseases, has been experiencing steady growth and is projected to continue this trend in the coming years. In 2023, the market was valued at approximately USD 144.11 billion and is expected to reach USD 207.78 billion by 2033, growing at a compound annual growth rate (CAGR) of 4% from 2024 to 2033. Specifically focusing on ischemic heart disease (IHD) drugs, the market was estimated at USD 6.1 billion in 2023 and is projected to grow to USD 7.2 billion by 2030, with a CAGR of 2.4% during this period.

The heart failure therapeutics segment is anticipated to witness significant growth, with sales expected to increase from USD 13.5 billion in 2022 to USD 33.7 billion by 2032, reflecting a robust CAGR of 9.6%.

In the context of cardiomyopathy treatments, the market in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) is projected to exhibit a CAGR of 6.13% during the period from 2025 to 2035.

The global market for heart disease medications is experiencing significant growth, driven by the development of innovative therapies and strategic collaborations within the pharmaceutical industry.

One notable area of expansion is the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and life-threatening heart condition. Alnylam Pharmaceuticals recently received U.S. Food and Drug Administration approval for Amvuttra (vutrisiran) to treat adult patients with ATTR-CM. This injectable drug reduces the production of the disease-causing protein at its source, offering a new therapeutic option in a market currently dominated by Pfizer's Vyndaqel. The ATTR-CM treatment market is projected to surpass $11 billion in revenues by 2032.

Competition in this sector is intensifying. BridgeBio Pharma's acoramidis has shown positive results in late-stage studies and may soon receive approval, potentially challenging existing treatments. Analysts anticipate that Alnylam's Amvuttra could achieve sales nearing $5 billion by 2029, reflecting the substantial market potential for effective ATTR-CM therapies.

Beyond ATTR-CM, pharmaceutical companies are actively pursuing advancements in cardiovascular treatments. AstraZeneca, for instance, has entered into a $2 billion licensing agreement with China's CSPC Pharmaceutical Group to develop an experimental drug targeting dyslipidaemia, a condition characterized by unhealthy cholesterol levels that increase the risk of heart disease. This collaboration underscores AstraZeneca's commitment to enhancing its cardiovascular portfolio and addressing prevalent risk factors associated with heart disease.

In the medical device arena, Edwards Lifesciences reported robust growth in its transcatheter aortic valve replacement (TAVR) procedures, generating $1.04 billion in sales during the fourth quarter—a 6% year-over-year increase. TAVR offers a less invasive alternative to open-heart surgery for patients with aortic valve disease, and its expanding adoption reflects the growing demand for innovative heart disease treatments.

Overall, the heart disease medicines market is poised for continued growth, propelled by ongoing research, strategic partnerships, and the introduction of novel therapies addressing both rare and common cardiovascular conditions.

Accreditation

All major Conference Series Conferences are accredited with Continuing Education (CE), Continuing Professional Development (CPD) and Continuing Medical Education (CME) credits respectively.

CME Credits:

Continuing Medical Education (CME) refers to a specific form of continuing education that helps medical professionals to maintain competence and learn about new and developing areas of their field. Conference Series Conferences are recognised and accredited with CME credits to enhance the professional abilities and skills of participants. CME credits are important to physicians because they require a specified number of credits annually to maintain medical licenses. CME credits are authorized by the Accreditation Council for Continuing Medical Education. Attending CME accredited conference is beneficial and valuable to physicians and other medical professional as it is a source of constant improvement that ultimately improves their medical practice, and keeps them up-to-date on the latest technologies, advancements, treatments, etc. Speaking at CME activities can also be a great stage for clinical medical professionals to share their expertise and increase their distinction in their specialty.

CE Credits:

Continuing Education (CE) credit is a measure used in continuing education programs to assist the professional to maintain his or her license in their profession. Conference Series Conferences provides ample opportunities to acquire CE credits. CE can open up previously closed doors and lead to better job opportunities. CE usually refers to college courses or other vocational training obtained by older adults or working professionals. CE credits work as carrier promoter and hold great value in medical, clinical and other areas of research even after completion of degrees in concerned field of research. It is pivotal in today’s world to get updated information on your field of research and profession. Attending Continuing Education Conferences can help expand your network and make connections that could translate into profitable relationships or job opportunities down the line. It also plays a vital role in recruiting new team members for an employer with open positions. CE helps licensing organizations and professional membership groups. Continuing Education promotes high quality performance, keep professionals up to date with the latest advances, and provide excellent networking opportunities.

CPD Credits:

Continuing Professional Development (CPD) is the holistic commitment of professionals towards the enhancement of personal skills and proficiency throughout their careers. It enables learning to become conscious and proactive, rather than passive and reactive. CPD accreditation is important because it ensures that courses provided adhere to the highest educational standards and international benchmarks of quality and learning. CPD enriches your knowledge, keeps you currently competent and is the key to career progression and professional growth. There are many advantages to carrying out CPD that includes filling gaps in your knowledge and skills to become more productive and efficient, building confidence and credibility to stand out from the crowd, achieving your career goals and demonstrating professional status. CPD hours can be earned through continuing education, leadership activities, instructional activities, completion of significant work projects, research and publications. Conference Series Conferences have been accredited with CPD credits to expedite the progress of research and industry professionals.

Past Conference Report

Heart Congress 2024

We had a huge success with the completion of 13^th World Heart Congress which was held in December 12-13, 2024 in Rome, Italy. The significance of the meeting was achieved due to the accumulation of all the related group of spectators of research scientists to share their Knowledge, Research work, Technologies, and furthermore trade of worldwide Information towards the correct crowd at ideal time. Congress has received a generous response from all over the world. This has been organized with the aim of endorsing the development of new perceptions and ideas for investigating the high level of knowledge reached by scientific community in the field of heart.

The conference was organized around the theme “Pulsating Progress: Advancements Shaping the Future of Cardiology”. The congress entrenched a firm relation of future strategies in the field of heart, We would like to thank each and every participant of World Heart Congress 2024 to make this a huge success. And special thanks to media partners for the promotion of our event, The Conference Series Conferences aim to bring together the prominent researchers’ academic scientists, and research scholars to exchange and share their experiences on all aspects of heart. It is conjointly a knowledge domain platform for researchers, practitioners and educators to gift and discuss the foremost recent advances, trends, and issues in addition as sensible challenges and solutions adopted in the fields of heart, Conference Series LLC Ltd is glad to announce its “14^th World Heart Congress, going to be held during September 22-23, 2025 in Dubai, UAE. We cordially welcome all the eminent Researchers, Scientists and Professors to be part of this prestigious conference, Bookmark your dates for “World Heart Congress 2025,” as the Nominations for Best Poster Awards and Young Researcher Awards are open across the world.